Barclays’s Tenax Therapeutics TENX Stock Holding History

Barclays’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$235K	Buy	124,205 +116,151	+1,442%	+$875K	﹤0.01%	3869
2026 Q2	$117K	Sell	8,054 -8,644	-52%	-$110K	﹤0.01%	3971
2026 Q1	$267K	Buy	+16,698	New	+$226K	﹤0.01%	3527
2025 Q3	–	Sell	-11	Closed	-$63	–	5727
2025 Q2	$63	Buy	+11	New	+$64	﹤0.01%	5112
2019 Q4	–	Hold	0	–	–	–	6803
2019 Q3	–	Hold	0	–	–	–	7119
2019 Q2	–	Hold	0	–	–	–	7270
2019 Q1	–	Hold	0	–	–	–	7321
2018 Q4	–	Hold	0	–	–	–	7318
2014 Q2	–	Hold	0	–	-$1K	–	7801
2014 Q1	–	Sell	-1	Closed	-$198K	–	7486
2013 Q4	$67K	Buy	+1	New	+$135K	﹤0.01%	5971

Other funds holding TENX

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Barclays's TENX Position: Q3 2026 in Review

Barclays increased its Tenax Therapeutics (TENX) stake by 1,442% in Q3 2026, buying an estimated $875K and bringing the position to 124,205 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #3869.

Barclays first reported a position in TENX in Q4 2013 and has held it in 5 quarters since. The position peaked at $267K in Q1 2026. 29 funds tracked by Wall St. Rank hold TENX as of Q3 2026.

Barclays held 124,205 shares of Tenax Therapeutics worth $235K as of Q3 2026.
Barclays bought 116,151 Tenax Therapeutics shares in Q3 2026, an estimated $875K.
Tenax Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3869 holding.
Barclays first reported a position in Tenax Therapeutics in Q4 2013 and has held it in 5 quarters since.
Barclays's Tenax Therapeutics position peaked at $267K in Q1 2026.
29 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.